ClinicalTrials.gg
CompletedNCT06004037Updated Jul 10, 2026

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

A Phase 2 interventional study of Delpazolid in Nontuberculous Mycobacterium Infection and Mycobacterium Abscessus Infection, sponsored by LigaChem Biosciences, Inc.. Completed at 5 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by LigaChem Biosciences, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of delpazolid add-on therapy in Patients with Refractory Mycobacterium abscessus Complex Pulmonary disease

Read the detailed description

Delpazolid, which demonstrates effects similar to other oxazolidinone-class drugs and has confirmed good safety, aims to evaluate its efficacy in MABC-PD patients who are unresponsive to guideline-based treatments

02

Conditions studied

  • Nontuberculous Mycobacterium Infection
  • Mycobacterium Abscessus Infection

Keywords

  • NTM
  • MABC
  • MABC-PD
  • rapid growers
03

In context

Mycobacterium Infections, Nontuberculous

54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.

This study's enrollment of 24 is below the median of 40 across 35 interventional studies indexed under Mycobacterium Infections, Nontuberculous.

Browse Mycobacterium Infections, Nontuberculous studies →

Lead sponsor

LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-screening: Adults aged 19 years or above
  • Pre-screening: Patients diagnosed with MABC (including subspecies abscessus, bolletii, and massiliense) pulmonary disease in radiologic and microbiologic evaluations
  • LCB01-0371 MIC ≤ 8 μg/mL for MABC
  • Patients who continue to show positivity for MABC even after treatments based on the guidelines of ATS/ERS/ESCMID/IDSA for at least 6 months prior to screening, and who meet all of the following criteria:

    1. Patients who have been confirmed positive at least once in the last sputum or bronchoscopy sample culture performed prior to screening
    2. Patients who have not achieved culture conversion (at least 3 consecutive negative mycobacteria cultures in the sputum or bronchoscopy sample collected at an interval of at least 4 weeks) within 6 months prior to screening
  • Patients who can voluntarily expectorate sputum at screening
  • Patients with a of 12 weeks or more
  • Patients with adequate organ function who meet the following criteria:

    1. > 9.0 g/dL (without transfusion within 2 weeks prior to measurement)
    2. ≥ 1,500/µL (without administration of G-CSF within 2 weeks prior to measurement)
    3. ≥ 100,000/µL
    4. Total ≤ 1.5 × (ULN)
    5. /aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN
    6. Serum creatinine ≤ 1.5 × ULN or >30 mL/min (calculated with the Cockcroft-Gault formula)
  • Patients who voluntarily provided a written consent to participate in the clinical study

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot swallow the study drug tablet due to dysphagia, nasogastric tube insertion, etc.
  • Patients diagnosed with cystic fibrosis
  • Patients who have received a lung transplant
  • Patients with disseminated or extrapulmonary nontuberculous mycobacteria
  • Patients with known active pulmonary tuberculosis
  • Patients with NTM infections other than MABC
  • Patients with an active pulmonary within 1 year prior to screening or Patients with other malignancies that require chemotherapy or radiotherapy
  • Patients who has received linezolid for MABC treatment within 3 months prior to screening
  • Patients with known positivity or a suspected infection thereof or Patients with a known active or C infection
  • Patients who currently have a cardiovascular disease

    1. Patients with severe cardiac failure ( [NYHA] class III/IV) that occurred within 24 weeks prior to screening
    2. Patients with pulmonary embolism or deep venous thrombosis that occurred within 24 weeks prior to screening
  • Patients whose multidrug therapy for treatment of MABC was changed within 4 weeks prior to screening (Discontinuation, dose adjustment, change of administration route, etc., are allowed.)
  • Patients for whom the administration of concomitant drugs that correspond to the following cannot be discontinued during the clinical study or for whom their administration is necessary

    1. Administration of a new antibacterial agent for the prioritized treatment of NTM, especially MABC, other than background therapy
    2. Monoamine oxidase inhibitors
    3. Serotonin reuptake inhibitor or serotonin 5-HT1 receptor agonists
    4. Meperidine or buspirone
    5. Drugs that lower epilepsy threshold; tramadol, etc.
    6. Tricyclic Antidepressant
    7. Other products: If there is a history of administration within 30 days prior to screening, it falls under the exclusion criteria.
  • Pregnant or breastfeeding women and women of who do not agree to practice appropriate methods*:
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    delpazolid

    In addition to background therapy for MABC, patients will be given orally three tablets (400 mg/tablet) of LCB01-0371 for 12 weeks.

    Drug: Delpazolid

Interventions

  • Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks. After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total.

    Also known as: LCB01-0371

06

What researchers measure

Primary outcomes

  1. semi-quantitative scale (SQS) change versus baseline

    The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in SQS

    The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load.

    Time frame: 4 weeks and 8 weeks

  2. Sputum culture conversion rate

    neg culture x3( sputum conversion)

    Time frame: 12 weeks

  3. Time to culture conversion

    from the date of assignment to the first negative result.

    Time frame: 12 weeks

  4. Time to positivity in the liquid culture automated system (MGIT)

    time to detection of positive in MGIT system

    Time frame: 12 weeks

  5. Negative sputum culture rate at each time point after baseline

    negative culture results in MGIT and solid media

    Time frame: 12 weeks

  6. Change from baseline in the inflammatory marker

    erythrocyte sedimentation rate \[ESR\]) at each time point

    Time frame: 12 weeks

  7. Change from baseline in the CT score

    The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. Descriptive statistics for each point in time are presented, and intra-group comparison of CT score changes at 12 weeks compared to baseline

    Time frame: 12 weeks

  8. Quality of Life Questionnaire-Bronchiectasis

    The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.

    Time frame: 12 weeks

  9. Six-minute walk test

    Six-minute walk test

    Time frame: 12 weeks

  10. Extended administration

    1\) SQS at each time point compared to baseline in subjects receiving extended administration * The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load 2) Inflammatory markers at each time point compared to baseline in subjects receiving extended administration * erythrocyte sedimentation rate 3) CT scores at each time point compared to baseline in subjects receiving extended administration * The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. 4\) QOL-B change at each time point compared to baseline in subjects receiving extended administration * The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. 5\) sputum culture negative conversion at each time point compared to baseline in subjects receiving extended administration * negative culture results in MGIT and solid media

    Time frame: After 12 weeks

07

Study locations

5 sites
  • Asan Medical Center
    Seoul, South Korea
  • Bundang Seoul National University Hospital
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Bundang Hospital
    Seoul, South Korea
  • Severance Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Sep 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 22, 2023
StartActual
Jan 16, 2024
Primary completionActual
Sep 15, 2025
CompletionActual
Jun 29, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06004037
Lead sponsor
LigaChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Jan 16, 2024
Primary completion
Sep 15, 2025
Completion
Jun 29, 2026
Last update
Jul 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpazolid

Start the discussion